tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TARA Stock Latest News

Protara Therapeutics completes first cohort in Phase 2 trial of TARA-002
The FlyProtara Therapeutics completes first cohort in Phase 2 trial of TARA-002
10d ago
TARA
Protara Therapeutics announce results from THRIVE-1 study
PremiumThe Fly
Protara Therapeutics announce results from THRIVE-1 study
10d ago
TARA
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
PremiumPress Releases
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
10d ago
TARA
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
PremiumPress Releases
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
10d ago
TARA
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PremiumPress Releases
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
16d ago
TARA
Protara Therapeutics price target lowered to $25 from $30 at Oppenheimer
PremiumThe FlyProtara Therapeutics price target lowered to $25 from $30 at Oppenheimer
1M ago
TARA
Protara Therapeutics price target lowered to $20 from $22 at Guggenheim
Premium
The Fly
Protara Therapeutics price target lowered to $20 from $22 at Guggenheim
1M ago
TARA
Protara Therapeutics sees cash runway into 2026
Premium
The Fly
Protara Therapeutics sees cash runway into 2026
1M ago
TARA
Protara Therapeutics reports Q2 EPS (45c), consensus (80c)
PremiumThe Fly
Protara Therapeutics reports Q2 EPS (45c), consensus (80c)
1M ago
TARA
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
PremiumPress Releases
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
1M ago
TARA
TARA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
TARA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
TARA
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3M ago
TARA
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
PremiumPress ReleasesProtara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
4M ago
TARA
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
Premium
Stock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
4M ago
OPT
TARA
Protara Therapeutics files to sell 21.69M shares of common stock for holders
Premium
The Fly
Protara Therapeutics files to sell 21.69M shares of common stock for holders
5M ago
TARA
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
PremiumPress Releases
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
5M ago
TARA
Protara Therapeutics reports Q1 EPS (97c), consensus (92c)
PremiumThe Fly
Protara Therapeutics reports Q1 EPS (97c), consensus (92c)
5M ago
TARA
Protara Therapeutics price target raised to $30 from $26 at Oppenheimer
PremiumThe Fly
Protara Therapeutics price target raised to $30 from $26 at Oppenheimer
5M ago
TARA
Protara Therapeutics Launches $45M Private Placement Drive
PremiumCompany Announcements
Protara Therapeutics Launches $45M Private Placement Drive
6M ago
8K
TARA
Protara Therapeutics announces $45M private placement financing
PremiumThe FlyProtara Therapeutics announces $45M private placement financing
6M ago
TARA
Protara Therapeutics announces three-month data from TARA-002 program
Premium
The Fly
Protara Therapeutics announces three-month data from TARA-002 program
6M ago
TARA
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Premium
Press Releases
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
6M ago
TARA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >